New Rhein Healthcare Investors
Evan Tzanis is a seasoned executive in the biopharmaceutical industry with extensive experience in research and development, clinical operations, and strategic management. Currently serving as Executive in Residence at New Rhein Healthcare Investors since December 2019, Tzanis previously held prominent leadership roles, including Chief Operating Officer and Executive Vice President of Research and Development at Neuraptive Therapeutics, where responsibilities encompassed daily operations, financing activities, and strategic planning. Tzanis also served as Chief Development Officer at Paratek Pharmaceuticals, leading development programs and participating in organizational initiatives. Additional experience includes senior roles at Endo Pharmaceuticals and Pfizer, along with early career positions at Quintiles and RRD International, LLC. Tzanis holds a Bachelor’s degree in Experimental Psychology from Villanova University and further academic experience from the University of Vermont.
This person is not in any teams
This person is not in any offices
New Rhein Healthcare Investors
New Rhein is a Venture Capital/ Private Equity investor. Its partners are former pharmaceutical industry executives having both operational and M&A experience. New Rhein invests in healthcare companies with the objective of helping management teams build their business into a profile strategic investors would find attractive. We use our knowledge of what strategic buyers want and our relationships to help our portfolio companies achieve this goal. Investment areas of focus include specialty Rx (eg hospital), branded and difficult to make Gx, OTC, biologics, vaccines, and emerging markets (in particular China and Brazil). We are interested in product only deals, carve-outs and entire company purchases.